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BACKGROUND AND PURPOSE
Levetiracetam, a novel antiepileptic drug, has recently been shown to have antinociceptive effects in various animal models of
pain. The purpose of this study was to investigate the antihyperalgesic effect of levetiracetam and its mechanism of action, by
examining the involvement of GABAergic, opioidergic, 5-hydroxytryptaminergic (5-HTergic) and adrenergic systems in its effect,
in a rat model of inflammatory pain.
EXPERIMENTAL APPROACH
Rats were intraplantarly injected with the pro-inflammatory compound carrageenan. A paw pressure test was used to
determine: (i) the effect of levetiracetam on carrageenan-induced hyperalgesia; and (ii) the effects of bicuculline (selective
GABAA receptor antagonist), naloxone (non-selective opioid receptor antagonist), methysergide (non-selective 5-HT receptor
antagonist) and yohimbine (selective a2-adrenoceptor antagonist) on the antihyperalgesic action of levetiracetam.
RESULTS
Levetiracetam (10–200 mg·kg-1; p.o.) significantly reduced, in a dose-dependent manner, the inflammatory hyperalgesia
induced by carrageenan. The antihyperalgesic effect of levetiracetam was significantly decreased after administration of
bicuculline (0.5–2 mg·kg-1; i.p.), naloxone (1–3 mg·kg-1; i.p.), methysergide (0.25–1 mg·kg-1; i.p.) and yohimbine
(1–3 mg·kg-1; i.p.).
CONCLUSIONS AND IMPLICATIONS
These results show that levetiracetam produced antihyperalgesia which is at least in part mediated by GABAA, opioid, 5-HT
and a2-adrenergic receptors, in an inflammatory model of pain. The efficacy of levetiracetam in this animal model of
inflammatory pain suggests that it could be a potentially important agent for treating inflammatory pain conditions in
humans.
Abbreviations
d (g), difference between the pressure applied to the non-inflamed vs. the inflamed paw; %AA, % antihyperalgesic
activity; %I, % inhibition of antihyperalgesic activity; i.pl., intraplantar
Introduction
Antiepileptic drugs are widely used to treat multiple
non-epileptic disorders such as neuropathic and
inflammatory pain, migraine, essential tremors and
psychiatric disorders. These pathophysiological pro-
cesses disturb neuronal excitability by modulating
ion channels, receptors and intracellular signalling
pathways, all of which serve as targets for pharma-
cological actions of different antiepileptic drugs
(Guindon et al., 2007; Johannessen Landmark,
2008).
Levetiracetam ([S]-a-ethyl-2-oxo-1-pyrrolidine
acetamide) is a novel antiepileptic drug with a broad
spectrum of anticonvulsant activity and an unusu-
ally high safety margin (De Smedt et al., 2007). Its
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analgesic properties are also a point of interest.
Increasing evidence for antinociceptive effects of
levetiracetam has been obtained in different animal
models of pain. Experiments performed in rats show
that levetiracetam exerts antihyperalgesic effects in
a painful diabetic neuropathy (Ardid et al., 2003), in
anaesthetic-induced hyperalgesia (Archer et al.,
2007) and against postoperative pain (Silva et al.,
2008). There is also preliminary clinical evidence for
the efficacy of levetiracetam in treating trigeminal
neuralgia (Jorns et al., 2009) and chronic pain asso-
ciated with multiple sclerosis (Rossi et al., 2009).
Despite this information, the mechanism of the
antinociceptive effects of levetiracetam has not been
elucidated.
Numerous studies have demonstrated antinoci-
ceptive effects of antiepileptic drugs in animal
models of inflammatory pain (Field et al., 1997;
Tomic´ et al., 2004; Stöhr et al., 2006; Vucˇkovic´ et al.,
2006; Stepanovic´-Petrovic´ et al., 2008). In the
present study we examined whether levetiracetam,
administered by the clinically preferred oral route,
had an antihyperalgesic effect in the carrageenan-
induced model of inflammatory pain in the rat. In
addition, the potential involvement of adrenocep-
tors, GABA, opioid and 5-hydroxytryptaminergic
(5-HTergic) receptors in this antihyperalgesic effect
was investigated.
Methods
Animals
Experiments were performed on male Wistar rats
(Military Academy Breeding Farm, Belgrade, Serbia)
that weighed between 180 and 220 g. The animals
were housed in groups of four per cage (42.5 ¥ 27 ¥
19 cm) and maintained on a 12/12 h light/dark
cycle (lights were switched on at 06 h 00 min) at 22
 1°C and 60% relative humidity. Food and water
were available ad libitum except during the experi-
mental procedure. After arrival, the animals were
allowed to acclimatize for at least 3 days before
testing commenced. All experiments were carried
out at the same time of day between 8 h 00 min and
16 h 00 min to avoid diurnal variations in behav-
ioural tests. All experiments adhered to the guide-
lines of the Committee for Research and Ethical
Issues of IASP (Zimmermann, 1983). Efforts were
made to minimize the number of animals used. The
total number of animals used in this study was 161.
Paw pressure test
Antihyperalgesic activity was assessed by a modified
‘paw pressure’ test (Randall and Selitto, 1957; Tomic´
et al., 2004). The rat was placed with its hind paws
on two force transducer platforms of the apparatus
(Hugo Sachs Elektronik, March – Hugstetten,
Germany) and pushed slowly and smoothly down-
wards. Pressure was applied until one of the paws
received a force that exceeded the trigger level set at
100 g. At this point an audible click by the apparatus
was heard and measurement was stopped automati-
cally. The rat used its non-inflamed paw as the
weight-bearing limb in an attempt to spare the
inflamed paw. Thereby agents capable of reducing
the difference (d) between the pressure applied to
the non-inflamed vs. the inflamed paw were recog-
nized as possessing antihyperalgesic activity. The
forces applied to the paws were read on the display
and the difference (d) was calculated from the fol-
lowing equation:
d = ( ) −
( )
force g applied to the non-inflamed paw
force g applied to inflamed paw
The mean from four consecutive measurements at
each time point was used for further calculations.
The pretreatment d-value was obtained before
induction of inflammation by carrageenan as
described previously (Morris, 2003). The post-
treatment d-value was measured 30, 60, 90, 120, 180
and 240 min after drug administration. The
experimenter was blind to the treatment of the
animals.
The differences in force were expressed as the %
of antihyperalgesic activity (%AA) and calculated
according to the following formula (Tomic´ et al.,
2004):
%AA untreated carrageenan group average
treated carrage
= ([ −d
enan group average
untreated carrageenan group average
d
d
)
( )] × 100
If the treated carrageenan group average d was
greater than the untreated carrageenan group
average d, a value of 0%AA was assigned.
The values for %AA were calculated after each
measurement of d (30, 60, 90, 120, 180 and 240 min
after levetiracetam administration) to establish the
time of the peak effect. The ED50 (the dose that
expected to result in 50%AA) was estimated from
the corresponding log dose-response curves
(Tallarida, 2000).
In this study, six series of experiments were per-
formed (Figure 1). For each set of experiments,
control animals received the same volume of carra-
geenan intraplantarly (i.pl.) in the right hind paw
(Figure 1A). We first examined the antihyperalgesic
effects of levetiracetam (Figure 1B), followed by the
influence of bicuculline (Figure 1C line I), naloxone
(Figure 1D line I), methysergide (Figure 1E line I)
and yohimbine (Figure 1F line I) on the antihyper-
algesic actions of levetiracetam. All antagonists were
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injected i.p. immediately before levetiracetam (p.o.),
except for yohimbine, which was administered i.p.
15 min before levetiracetam. To exclude possible
intrinsic effects of the antagonists the highest
dose of each antagonist was tested separately
(Figure 1C–F lines II). Matching control groups of
animals received carrageenan (i.pl.), levetiracetam
(p.o.) and the same volume of saline (i.p.) instead of
the antagonists.
% inhibition (%I) of the antihyperalgesic effect
of levetiracetam by antagonists (bicuculline, nalox-
one, methysergide and yohimbine) was calculated
according to the following formula (Tomic´ et al.,
2004):
% %
% .
I AA with antagonist
AA without antagonist
= − (
) ×
100
100
The ID50 (the dose that was expected to result in
50%I) was estimated from the corresponding log
dose-response curves (Tallarida, 2000).
Drug administration
Levetiracetam (Kepra, UCB Pharma AG, 1630 Bulle,
Belgium) was suspended in distilled water and
sonicated for 15 min for proper drug distribution.
A homogeneous suspension of levetiracetam was
administered to rats by oral gavage (p.o.) in a
volume of 2 mL·kg-1 body weight. Bicuculline
hydrochloride (Sigma-Aldrich Chemie, Germany)
was dissolved in saline by addition of one drop of
10N HCl. Naloxone hydrochloride (Sigma-Aldrich
Chemie, Germany), methysergide maleate (Sigma-
Aldrich Chemie, Germany) and yohimbine hydro-
chloride (Sigma-Aldrich Chemie, Germany) were
dissolved in saline. All antagonists were injected
i.p. in a volume of 2 mL·kg-1 body weight. Carra-
geenan l (Sigma-Aldrich Chemie, Germany) was
suspended in saline and injected i.pl. into the right
hind paw of all animals, in a volume of 0.1 mL per
paw, using a 1 mL syringe and 24 gauge (0.55 ¥
25 mm) needle.
Figure 1
Experimental protocol used in evaluation of hyperalgesia induced by injection of carrageenan (CAR) into the right hind paw (A), the anti-
hyperalgesic effect of levetiracetam (LEV) (B), the effects of bicuculline (BIC) (C), naloxone (NLX) (D), methysergide (MTZ) (E) and yohimbine
(YOH) (F) on levetiracetam-induced anti hyperalgesia. i.pl., intraplantar.
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Drug and molecular target nomenclature con-
forms to the British Journal of Pharmacology’s
Guide to Receptors and Channels (Alexander et al.,
2008).
Statistical analysis
All computations were performed according to Tal-
larida (2000), using computer program Pharm Tools
Pro. Statistic analysis was performed according to
Dawson-Saunders and Trapp (1994), using SPSS 15
for Windows. The results are presented as mean
values  SEM obtained from groups of 6–8 animals.
Differences between the corresponding means were
verified by analysis of variance with repeated mea-
sures (one-way ANOVA), followed by Bonferroni test.
A P-value of less than 0.05 was considered statisti-
cally significant.
Results
The effect of levetiracetam on
carrageenan-induced hyperalgesia
In the paw pressure test in rats we observed that
administration of levetiracetam (10–200 mg·kg-1;
p.o.) caused a significant dose-dependent reduction
of carrageenan-induced hyperalgesia (Figure 2). The
antihyperalgesic effect of levetiracetam reached its
maximum 120 min after p.o. application (small
graph in Figure 2). The corresponding ED50 SEM at
the peak effect point was 26.7  2.2 mg·kg-1.
The influence of bicuculline on the
antihyperalgesic effect of levetiracetam
Bicuculline (0.5–2 mg·kg-1; i.p.) caused a significant
decrease in the antihyperalgesic effect of levetirac-
etam (100 mg·kg-1; p.o.) (Figure 3A). The maximal
inhibitory effects of bicuculline on levetiracetam-
induced antihyperalgesia were achieved 60 min
after i.p. administration; the corresponding values
are shown in Figure 4. The estimated ID50  SEM for
bicuculline at the peak effect point was 0.5 
0.4 mg·kg-1. Bicuculline itself (2 mg·kg-1; i.p.) did
not have an intrinsic effect in this experimental
model (Figure 3A).
The influence of naloxone on the
antihyperalgesic effect of levetiracetam
Naloxone (1–3 mg·kg-1; i.p.) significantly decreased
the antihyperalgesic effect of levetiracetam
(100 mg·kg-1; p.o.) (Figure 3B). The maximal inhibi-
tory effects of naloxone were achieved 90 min after
i.p. application; the corresponding values are pre-
sented in Figure 4. The estimated ID50  SEM for
naloxone at the peak effect point was 0.7 
0.3 mg·kg-1. The highest dose of naloxone tested did
Figure 2
Time-course of the antihyperalgesic effect of levetiracetam (LEV)
expressed as the difference in pressure g (d) applied to non-inflamed
and inflamed [carrageenan (CAR)-injected] rat hind paws. Pretreat-
ment d (plotted on the vertical axis) was obtained before CAR injec-
tion (i.pl.). Levetiracetam (p.o.) was given 60 min after induction of
inflammation (denoted by arrows). Each point represents the mean
 SEM of paw pressure differences (d) of 6–8 animals. Statistical
significance (*P < 0.05, **P < 0.01; one-way ANOVA with repeated
measures followed by Bonferroni test) was determined by comparing
the curve with that for the vehicle. Upper (small) graph: time course
of the antihyperalgesic effect of LEV expressed as a % of the antihy-
peralgesic activity (%AA). For symbols see the larger graph. i.pl.,
intraplantar.
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Figure 3
Time course of the inhibitory effects of bicuculline (BIC) (A), naloxone (NLX) (B), methysergide (MTZ) (C) and yohimbine (YOH) (D) on the
antihyperalgesic effect of levetiracetam (LEV), expressed as the difference in pressure g (d) applied to non-inflamed and inflamed (CAR-injected)
rat hind paws. Pretreatment d (plotted on the vertical axis) was obtained before induction of inflammation. BIC (i.p.) (A), NLX (i.p.) (B), MTZ (i.p.)
(C) were injected immediately prior to LEV administration (p.o.) and 60 min after injection of CAR; only YOH (i.p.) (D) was injected 15 min before
LEV and 45 min after CAR (denoted by arrows). Each point represents the mean  SEM of paw pressure differences (d) of 6–8 animals. Statistical
significance (*P < 0.05, **P < 0.01; one-way ANOVA with repeated measures followed by Bonferroni test) was determined by comparison of the
curves obtained in the presence of the receptor antagonists with the curve for saline + LEV. i.pl., intraplantar.
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not induce a significant change in the hyperalgesia
induced by carrageenan (Figure 3B).
The influence of methysergide on the
antihyperalgesic effect of levetiracetam
Methysergide (0.25–1 mg·kg-1; i.p.) significantly
decreased the antihyperalgesic effect of levetirac-
etam (100 mg·kg-1; p.o.) (Figure 3C). The peak
effects of methysergide were observed 60 min after
i.p. administration; the values of maximal %I are
shown in Figure 4. The estimated ID50  SEM for
methysergide at the maximal effect point was 0.1 
0.2 mg·kg-1. The highest dose of methysergide used
(1 mg·kg-1; i.p.) did not affect carrageenan-induced
hyperalgesia in this experimental model
(Figure 3C).
The influence of yohimbine on the
antihyperalgesic effect of levetiracetam
Pretreatment with yohimbine (1–3 mg·kg-1; i.p.) sig-
nificantly decreased the antihyperalgesic effect of
levetiracetam (100 mg·kg-1; p.o.) (Figure 3D). The
maximal inhibitory effects of yohimbine were
achieved 90 min after i.p. injection; the correspond-
ing values are presented in Figure 4. The estimated
ID50  SEM for yohimbine at the peak effect point
was 2.0  0.1 mg·kg-1. The highest dose of yohim-
bine tested did not affect carrageenan-induced
hyperalgesia (Figure 3D).
Discussion
In the present study we showed for the first time,
the antihyperalgesic effect of levetiracetam and its
mechanisms of action in a model of inflammatory
pain. Similar to our results, it has been demon-
strated that systemic carbamazepine, oxcarbazepine
and lamotrigine also inhibit hyperalgesia, induced
by pro-inflammatory agents, in the paw pressure
test in rats (Nakamura-Craig and Follenfant, 1995;
Tomic´ et al., 2004; Vucˇkovic´ et al., 2006; Stepanovic´-
Petrovic´ et al., 2008). In contrast to our results,
Munro et al. (2007) did not observe any antihyper-
algesic activity of levetiracetam in their experimen-
tal model of formalin-induced inflammatory pain in
rats, despite the use of higher doses of levetiracetam
than in our study (100–600 mg·kg-1 vs.
10–200 mg·kg-1). The reason for this discrepancy
might be due to the use of different pro-
inflammatory compounds (formalin vs. carrageenan
in our study) and/or due to different routes of leve-
tiracetam administration (i.p. vs. p.o. in our study).
The dose-range (10–200 mg·kg-1) used in our study
is comparable to the doses effective in animal
models of epilepsy (Klitgaard et al., 1998).
The finding that bicuculline (0.5–2 mg·kg-1; i.p.),
a selective GABAA receptor antagonist, significantly
decreased the antihyperalgesic effect of levetirac-
etam, indicates that GABAA receptors are involved in
its action. This could be interpreted in two ways.
Levetiracetam could either act on GABAA receptors
directly or indirectly by enhancing GABAergic neu-
rotransmission. There is evidence that levetiracetam
does not have a significant affinity for GABA recep-
tors (Gower et al., 1992; Noyer et al., 1995; De Smedt
et al., 2007). On the other hand, several indirect
effects of levetiracetam on GABAergic neurotrans-
mission have been reported. Hence, levetiracetam
could potentiate GABA-mediated inhibition, possi-
bly via changes in GABA metabolism and turnover
that are secondary to the postsynaptic effects of the
drug (Löscher et al., 1996) or through regulation of
GABA transporters (Ueda et al., 2007). Levetiracetam
has been shown to reverse the action of negative
allosteric modulators on GABAA ionotropic recep-
tors and facilitate GABA-mediated inhibition (Rigo
et al., 2002). Taken together with our results,
this suggests that levetiracetam acts on GABAA
receptors indirectly, by augmenting GABAergic
neurotransmission.
The possible involvement of the opioidergic
system in the antihyperalgesic effect of levetirac-
etam in the inflammatory paw pressure test was
investigated by pretreatment with naloxone, a non-
selective opioid receptor antagonist. Naloxone
(1–3 mg·kg-1; i.p.) decreased the antihyperalgesic
effect of levetiracetam. Although a binding study of
levetiracetam on opioid receptors has yet to be
carried out, several in vitro studies have revealed that
levetiracetam selectively inhibits the N-type Ca2+
Figure 4
Inhibitory effects of bicuculline (BIC), naloxone (NLX), methysergide
(MTZ) and yohimbine (YOH) on the antihyperalgesic effect of leve-
tiracetam, expressed as a % of inhibition (%I), obtained at the time
of maximal effect of antagonists.
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channels and reduces Ca2+ conductance (Niespod-
ziany et al., 2001; Lukyanetz et al., 2002). Opioid
receptor agonists also inhibit N-type Ca2+ channels
in a voltage-dependent manner (Wu et al., 2004).
Hence, levetiracetam, by influencing N-type Ca2+
channels, might incorporate opioid-induced anti-
nociception in its effects.
To elucidate the antinociceptive profile of leveti-
racetam in more detail, we tested the extent of its
dependence on the 5-HT system. 5-HT plays an
important role in modulating nociceptive transmis-
sion through both inhibitory and facilatory signal-
ling pathways. This dual action can be the result of
the mediation of different effects through different
5-HT receptors. Results obtained from electrophysi-
ological studies suggest that 5-HT1 receptors most
probably mediate a depressant action and antinoci-
ceptive effects, while 5-HT2 receptors usually
mediate membrane depolarization and pronocicep-
tive effects (Millan, 2002; Lopez-Garsia, 2006).
Methysergide (0.25–1 mg·kg-1; i.p.), a non-selective
5-HT receptor antagonist, significantly reduced the
antihyperalgesic effect of levetiracetam in the
inflammatory paw pressure test. There are no data
available on the binding properties of levetiracetam
to 5-HT receptors, nor on its ability to influence
5-HT release in nociceptive transmission. The results
obtained in the present study indicate that 5-HT
receptors (most probably 5-HT1) are involved in the
antihyperalgesic effect of levetiracetam. Subsequent
studies are needed to identify the receptor subtype.
The finding that yohimbine (1–3 mg·kg-1; i.p.), a
selective a2-adrenoceptor antagonist, decreased
significantly the antihyperalgesic effect of lev-
etiracetam implicates the involvement of a2-
adrenoceptors in its action. At present, there is no
information concerning the binding properties of
levetiracetam to a2-adrenoceptors and its ability
to influence brain noradrenaline levels. The
a2-adrenoceptors are widely distributed in the
peripheral and central nervous systems and could
mediate analgesia or hyperalgesia, depending on the
subtype of a2-adrenoceptor involved (Millan, 2002;
Sawynok, 2003). The a2-adrenoceptors are located
on primary afferent terminals, on the spinal dorsal
horn neurones and within several brainstem nuclei
that are implicated in analgesia (Petrovaara, 2006;
Chen et al., 2007). After systemic administration of
levetiracetam, the interaction with a2-adrenoceptors
that results in analgesia can occur at all of these
sites, either directly or indirectly. Further experi-
ments are needed to clarify the site and mode
of interaction between levetiracetam and a2-
adrenoceptors.
Interplay between opioidergic, 5-HT and norad-
renergic systems in pain modulation has been pro-
posed previously (Millan, 2002) and may be
necessary for providing maximal pain relief. There-
fore, activation of the opioidergic system, in addi-
tion to temporary activation of noradrenergic and
5-HT systems, might indicate that the analgesic
effect of levetiracetam depends on the interaction
of the descending inhibitory system, via 5-HT and
noradrenaline release, with the opioid inhibitory
system. It should be mentioned that the functional
status of opioid receptors (Zollner et al., 2003;
Vanegas and Schaible, 2004), 5-HT receptors
(Zhang et al., 2002) and a2-adrenoceptors (Vanegas
and Schaible, 2004) could be altered following
peripheral inflammation. These changes lead to an
increase in the number and sensitivity of these
receptors, resulting in an increase in the antinoci-
ceptive efficacy mediated by them. Accordingly,
Ardid et al. (2003) provided evidence that levetirac-
etam (540 mg·kg-1; i.p.) has only a weak anti-
nocieptive effect in the paw pressure test in naive
(carrageenan untreated) rats. It is possible that
levetiracetam activates the opioidergic antinocice-
ptive pathway, which in turn interacts with other
pain inhibitory systems. Moreover, Jasmin et al.
(2003) showed that GABAA receptor stimulation
from the cerebral cortex produces analgesia by
enhancing the descending inhibition of spinal
nociceptive neurones. The possible implication of
this is that enhancement of GABA transmission
by levetiracetam also increases the activity of
descending inhibitory, noradrenergic and 5-HT
pathways.
As levetiracetam modulates GABAAergic, opio-
idergic, 5-HT and a2-adrenergic systems through its
antihyperalgesic effect, a broad spectrum of side
effects could be expected. However, this antiepilep-
tic drug, which has been in use in humans for more
than 10 years is generally well-tolerated and in this
respect better than many other antiepileptic drugs
(De Smedt et al., 2007). Still, some of levetiracetam
side effects could be related to its non-specific
actions: nausea and vomiting could be the result of
its effects on the opioid and 5-HT systems; anorexia
could be due to its effect on 5-HT receptors; amnesia
and ataxia could be due to its effect on the GABAA
receptors; and headache could be a result of its effect
on a2-adrenoceptors.
In conclusion, the results of the present study
show that levetiracetam induces antihyperalgesia
in an inflammatory model of pain and that
this effect is at least in part, mediated by
a2-adrenoceptors, GABAA, opioid and 5-HT recep-
tors. Levetiracetam’s efficacy in this animal model
of inflammatory pain suggests that it could be a
potentially important agent for treating inflamma-
tory pain in humans.
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